• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference.

作者信息

Mills John R, Kohlhagen Mindy C, Willrich Maria A V, Kourelis Taxiarchis, Dispenzieri Angela, Murray David L

机构信息

Department of Laboratory Medicine and Pathology and.

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.

出版信息

Blood. 2018 Aug 9;132(6):670-672. doi: 10.1182/blood-2018-05-848986. Epub 2018 Jun 11.

DOI:10.1182/blood-2018-05-848986
PMID:29891533
Abstract
摘要

相似文献

1
A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference.一种消除治疗性单克隆抗体干扰导致的骨髓瘤假阳性的通用解决方案。
Blood. 2018 Aug 9;132(6):670-672. doi: 10.1182/blood-2018-05-848986. Epub 2018 Jun 11.
2
Interference of monoclonal antibody therapies with serum protein electrophoresis tests.
Clin Chem. 2010 Dec;56(12):1897-9. doi: 10.1373/clinchem.2010.152116. Epub 2010 Oct 12.
3
Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma: Frequency and Duration of Detection of Daratumumab and Elotuzumab.治疗性单克隆抗体对多发性骨髓瘤患者常规血清蛋白电泳和免疫固定的干扰：达妥木单抗和埃罗妥珠单抗的检测频率和持续时间。
Am J Clin Pathol. 2018 Jul 3;150(2):121-129. doi: 10.1093/ajcp/aqy037.
4
A New Monoclonal Band in a Patient with Refractory Multiple Myeloma.一名难治性多发性骨髓瘤患者出现新的单克隆条带。
Clin Chem. 2017 Apr;63(4):927-935. doi: 10.1373/clinchem.2016.270090.
5
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.监测接受达雷妥尤单抗治疗的多发性骨髓瘤患者：揭示单克隆抗体干扰。
Clin Chem Lab Med. 2016 Jun 1;54(6):1095-104. doi: 10.1515/cclm-2015-1031.
6
Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).达雷妥尤单抗会干扰多发性骨髓瘤患者的血清免疫固定电泳监测，使用达雷妥尤单抗免疫固定电泳反射检测（DIRA）可消除这种干扰。
Clin Chem Lab Med. 2016 Jun 1;54(6):1105-9. doi: 10.1515/cclm-2015-0888.
7
Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab.
Ann Clin Biochem. 2020 Mar;57(2):178-181. doi: 10.1177/0004563219894354. Epub 2019 Dec 27.
8
Impact of M-protein detection on the response evaluations of patients undergoing treatment with the IgG-κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents.M 蛋白检测对 IgG-κ 单克隆抗体达雷妥尤单抗或伊沙妥昔单抗治疗患者的疗效评估的影响，以及免疫固定电泳（IFE）系统和试剂之间的差异。
Cancer Med. 2024 Aug;13(16):e70128. doi: 10.1002/cam4.70128.
9
Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis.
Br J Haematol. 2011 Oct;155(1):123-5. doi: 10.1111/j.1365-2141.2011.08644.x. Epub 2011 Apr 27.
10
Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
Nefrologia. 2013 Nov 13;33(6):862-4. doi: 10.3265/Nefrologia.pre2013.Jul.12103.

引用本文的文献

1
Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma.在多参数质谱分析中监测M蛋白、治疗性抗体和多克隆抗体可深入了解多发性骨髓瘤患者的治疗反应动力学。
Pharmaceutics. 2025 Jan 19;17(1):135. doi: 10.3390/pharmaceutics17010135.
2
Top-down proteomics.自上而下蛋白质组学
Nat Rev Methods Primers. 2024;4(1). doi: 10.1038/s43586-024-00318-2. Epub 2024 Jun 13.
3
Bringing mass spectrometry into the care of patients with multiple myeloma.
将质谱分析引入多发性骨髓瘤患者的护理中。
Int J Hematol. 2022 Jun;115(6):790-798. doi: 10.1007/s12185-022-03364-2. Epub 2022 Apr 26.
4
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).在参与 STAMINA 试验（BMT CTN 0702/07LT）的多发性骨髓瘤患者中，Mass-Fix 比标准方法更能预测 PFS 和 OS。
Blood Cancer J. 2022 Feb 10;12(2):27. doi: 10.1038/s41408-022-00624-6.
5
Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.使用质谱法追踪达雷妥尤单抗的清除率：对M蛋白监测及达雷妥尤单抗再利用的影响
Leukemia. 2022 May;36(5):1426-1428. doi: 10.1038/s41375-021-01501-0. Epub 2022 Jan 29.
6
Minimal residual disease in multiple myeloma: why, when, where.多发性骨髓瘤的微小残留病：为何、何时、何地。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):37-45. doi: 10.1182/hematology.2021000230.
7
Sensitive multiple myeloma disease monitoring by mass spectrometry.通过质谱法进行灵敏的多发性骨髓瘤疾病监测。
Blood Cancer J. 2021 Apr 29;11(4):78. doi: 10.1038/s41408-021-00473-9.
8
Antibody-Based Treatment Approaches in Multiple Myeloma.基于抗体的多发性骨髓瘤治疗方法。
Curr Hematol Malig Rep. 2021 Apr;16(2):183-191. doi: 10.1007/s11899-021-00624-6. Epub 2021 Mar 17.
9
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients.MASS-FIX 检测法在常规临床实践中对单克隆蛋白和轻链 N-糖基化的检测：一项 6315 例患者的横断面研究。
Blood Cancer J. 2021 Mar 4;11(3):50. doi: 10.1038/s41408-021-00444-0.
10
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.质谱法评估多发性骨髓瘤和相关疾病中的单克隆蛋白：国际骨髓瘤工作组质谱学委员会报告。
Blood Cancer J. 2021 Feb 1;11(2):24. doi: 10.1038/s41408-021-00408-4.